Background and Aims: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. 
Introduction
Risk factors for cancer in inflammatory bowel disease [IBD] are still debated. 1 Thiopurines [IS] have been reported to increase the risk of lymphoma 1,2 and of non-melanoma skin cancers [NMSC] , particularly in Crohn's disease [CD] . 3, 4 The cancer risk associated with tumour necrosis factor-α [TNFα] antagonists is undefined, due to the relatively short follow-up [first trial published in 1995] and to the frequently combined treatment with IS. 5, 6 Nevertheless, TNFα antagonists currently appear not to increase the risk of cancer overall, as supported by a multicentre case-control study in 2006. 7, 8 and by several independent studies. 1, 9, 10, 11, 12 An increased risk of melanoma has been reported using TNFα antagonists in IBD. 13, 14 Hepatosplenic T-cell lymphoma [HSTCL] has been associated with thiopurine use, particularly in young male patients with CD, treated with combined TNFα antagonists. 15, 16 However, the absolute risk of these cancers appears to be low.
Recently, research has been focused on the cancer risk associated with IS and/or anti-TNFα treatments. Conversely, the role of clinical characteristics of IBD in determining the cancer risk when using any immunomodulator [IMM] has been less extensively investigated. In 2012, in a single-centre study we indicated penetrating CD and pancolitis in ulcerative colitis [UC] as significant risk factors for cancer overall. 17 In 2013, a Danish study indicated CD phenotype as a risk factor for cancer. 18 To the best of our knowledge, the role of clinical characteristics and phenotype of IBD in determining the cancer risk in relation to IMM treatments is currently undefined. This issue may assume relevance due to the frequent use of IMM in IBD, particularly in young patients with severe and chronically active disease.
In order to address these issues, we aimed to prospectively assess, in a multicentre nested case-control study, the incidence and characteristics of cancer in a cohort of IBD patients followed up for 3 years. The role of clinical characteristics of IBD vs the use of thiopurines and/or TNFα antagonists in determining the incidence of cancer was also investigated.
Materials and Methods

Study design
In a prospective multicentre, nested case-control study, all incident cases of cancer diagnosed in 16 
Study population
Inclusion criteria shared by IBD-K and IBD-C were: 1] diagnosis of CD or UC, defined according to current guidelines 5, 6 ; 2] diagnosis of IBD ≥ 6 months In this study, we aimed to confirm in a larger population findings from our single-centre study, 17 suggesting the role of IBD phenotype in determining the cancer risk. In our previous study, as in other studies 17, 20 , UC extent was subgrouped into distal [rectum and sigmoid colon], left-sided [or subtotal: up to the left flexure], and pancolitis [or extensive]. In order to confirm our findings and to calculate the sample size on the basis of our preliminary study, 17 UC was subgrouped into distal, left-sided [subtotal], and extensive [pancolitis] . 17, 20 In a separate analysis, UC was also subgrouped into proctitis, left-sided, and extensive. 6, 19 The accuracy of cancer incidence was provided by the written histological analysis of cancers [including date at diagnosis].
IBD phenotypes were defined only at enrolment, as described. 5, 6, 17, 20 In order to estimate with good accuracy cancer incidence in CD vs UC, the study involved only tertiary IBD centres and patients were assessed by experienced, senior, IBD-dedicated gastroenterologists, routinely following clinical practice guidelines and procedures in order to accurately assess: diagnosis of IBD, IBD phenotype, and malignancy diagnosis and classification. 5, 6, 32 In particular, the diagnosis of CD vs UC was defined on the basis of clinical, haematochemical, endoscopic, histological and radiological assessments, including colonoscopy with biopsies and small-bowel imaging (ie entero-magnetic resonance imaging [MRI] , enterocomputed tomography [CT] and/or small intestine contrast ultrasonography). 5, 6 The diagnosis and phenotype of IBD were assessed and eventually discussed before entry, and patients with unclassified or indeterminate IBD were not included in the study.
Statistical analysis
Calculation of the sample size should require the knowledge of the expected incidence of cancer not only in the general IBD population, but also in patients with different CD phenotypes and UC extent, with and without IS and/or anti-TNFα use. The risk of incident cancer when considering IBD phenotype, CD pattern, UC extent, and IMM use is undefined. Sample size calculation was therefore based on our study 17 assessing the cancer risk in CD vs UC patients treated or not treated with IMM, subgrouped according to CD phenotype, and UC extent subgrouped as described. 17 In our single-centre study, the incidence of cancer in UC and CD was 2.8% and 5.5%, respectively. 17 On the basis of this observation, we estimated that a minimum of 2001 person-years of follow-up would be needed to have a statistical power of 80% and type I error probability of 0.05 not to reject the hypothesis that CD-UC type relative risk is equal to 1.96 Figure 1 ]. As each of the 174 IBD-K patients was matched with two IBD patients without cancer, controls included 348 IBD patients [IBD-C]: 198 CD-C and 150 UC-C, without cancer. All the 522 IBD patients completed the 3 years' follow up. None of the 348 IBD-C showed cancer at entry according to the study protocol, and none of them developed cancer during the 3 years' follow up.
Results
Incidence of cancer
Clinical characteristics
The IBD group [n = 522] included 174 patients with incident cancer (CD-K: n = 99, 57%; UC-K: n = 75, 43%; age 57 Table 1 ]. The frequency of smokers was higher in CD-C than in UC-C [p < 0.0001] and comparable between CD-K vs UC-K. At diagnosis of cancer, the age was lower in CD patients with a B1 vs a B2 phenotype (47 vs 59.5 ; p = 0.005, respectively), whereas no differences were observed between CD patients with a B1 vs B3 (50 Table 3 ].
Characterization of incident cases of cancer
Lymphoma [four nonHodgkin, NHL, two Hodgkin, HL] occurred in six patients after the diagnosis of CD (six males, age at diagnosis of CD 38 ). In these six patients, the median age at diagnosis of lymphoma was 46 and CD duration at diagnosis of lymphoma was 9 years . Current or past use of both AZA and TNFα antagonists was reported in two of the six patients ( Figure 3a ]. Conversely, a comparable proportion of patients with vs without cancer was observed within patients with a non-penetrating non-stricturing or with stricturing CD [ Figure 3a ].
Incident cancer in CD vs UC
In patients with extensive UC there was a significantly higher proportion of patients with vs without cancer (extensive UC vs others: UC-K vs UC-C: 41/75 [55%] vs 51/149 [34%]) [ Figure 3b ]. The frequency of distal and left-sided UC was comparable between patients with vs without cancer [ Figure 3b ]. Comparable findings were observed when UC extent was subgrouped into proctitis, leftsided, and extensive disease.
In CD, multivariate analysis adjusted for the reported variables [age at the latest visit, smoking, current or past treatments with IS and TNFα antagonists, disease-related surgery, CD duration] identified a penetrating vs non-penetrating non-stricturing CD as a significant risk factor for cancer overall (OR 2. Inflammatory Bowel Disease Phenotype and Cancerrespectively) [ Figure 4c ]. In CD, disease-related surgery was at the limit of the statistical significance as risk factor for extracolonic cancers (OR 1.54 [0.77-3.10]) [ Figure 4c ]. In UC, disease-related surgery was the only significant risk factor for CRC (OR 3. 
Discussion
The benefits when using immunomodulators in IBD currently appear to outweigh the cancer risk.
1,2,5,6 Thiopurines and anti-TNFα treatments may increase the cancer risk by interfering with the immune response towards tumour cells. 1, 5, 6, 21 In 1975, TNFα was described as an endotoxin causing necrosis of tumours, thus suggesting that blocking this cytokine may reduce the suppression of cancer cells. 22 TNFα antagonists have been reported to increase melanoma risk. 13 In UC, disease-related surgery and extensive vs distal disease increased the overall cancer risk. Comparable findings were observed when UC extent was subgrouped into proctitis, left-sided, or extensive UC. Panel c. In CD, perianal disease was the only risk factor for colorectal cancer [CRC], whereas a penetrating vs non-penetrating non-stricturing behaviour and current or past treatment with thiopurines [IS] and TNFα antagonists were identified as risk factors for extracolonic cancers. Panel d. In UC, disease-related surgery was the only significant risk factor for CRC, whereas extensive vs distal and left-sided vs distal UC were identified as risk factors for extracolonic cancers. Comparable findings were observed when UC extent was subgrouped into proctitis, left-sided, and extensive disease.
However, the absolute risk of these cancers is low, 1, 2, 23, 24, 25, 26, 28 and a lower risk of CRC has been reported in patients with severe IBD treated with IMM. 29, 30, 31 The overall cancer risk associated with IMM use in IBD has been extensively investigated. 1, 2, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 23, 24, 25, 26, 27, 28 Conversely, evidence regarding the cancer risk associated with clinical characteristics of IBD vs the use of IMM treatments is lacking. 17, 18 We therefore investigated this issue in a prospective, multicentre, nested case-control study.
In our IBD population, the incidence of overall cancer was higher in CD than in UC, thus representing one of the main messages of the study. The low proportion of UC patients treated with IMM may be involved in this finding. A single-centre study reported an overall excess risk of cancer in CD, but not in UC, 18 in agreement with our retrospective study including a different IBD population. 17 Differences in terms of study design and populations may account for discrepant findings in this regard. 1, 32, 33 Moreover, to the best of our knowledge, data from prospective, multicentre, nested case-control studies including incident cancers are currently lacking. 1, 32, 33 To find whether IBD phenotype [CD vs UC] is a risk factor for cancer represented one of the aims of this study. Therefore, only patients with a definite diagnosis of UC or CD, according to current guidelines 5, 6 as judged by experienced, IBD-dedicated gastroenterologists referring to tertiary IBD centres, were enrolled. For proper assessment, cases requiring revisions in order to confirm the diagnosis [CD vs UC] were excluded before entry. Although any diagnosis, including of IBD [CD vs UC], may change over time, the methods applied provide evidence for an accurate diagnosis of CD vs UC in the tested population.
Multivariate analysis identified penetrating CD and extensive UC as risk factors for overall cancer and for extracolonic cancers, and this represented one of the main findings of the study. A higher frequency of penetrating CD and of extensive UC was observed in patients with vs without cancer, further supporting that severe inflammation may increase the cancer risk, as suggested by our retrospective study. 17 Extensive UC is a known risk factor for CRC. 1, 29, 32, 33 However, to the best of our knowledge, whether extensive UC and perforating CD may increase the risk of overall cancer and of extracolonic cancers is currently undefined. 1, 29, 32, 33 Comparable findings were observed when UC extent was subgrouped according to studies from our group 17 and others 20 or to current guidelines. 6, 19 Although IBD phenotype may have changed during the study period, IBD phenotypes were defined only at enrolment. Indeed, we aimed to assess the role of IBD phenotype vs IMM in determining the cancer risk, and at entry all cases [IBD-K] had an incident cancer according to the inclusion criteria. The present study therefore evaluated risk factors for cancer in IBD, when considering IBD phenotype defined at time of the diagnosis of cancer. In particular, IBD phenotype was defined at enrolment when considering the entire disease history, 5, 6, 17, 20 and the median IBD duration of the tested population was quite long [≥ 12 years in both CD and UC groups]. However, IBD phenotype may have changed in subgroups of patients during the few additional 3 years of follow-up. This is not the case for patients with a perforating phenotype in CD or with pancolitis in UC [identified as the two IBD subgroups at higher cancer risk in the present study] at enrolment. Although a large population [> 46 000 patients] was considered, whether these findings may be extended to the general IBD population is being evaluated in a longer follow-up.
A comparable proportion of IBD patients with or without cancer showed a current or past treatment with IS and/or TNFα antagonists. However, TNFα antagonists were used in a higher proportion of CD vs UC patients without cancer. Although almost half of UC patients showed extensive disease, IMM were used in a low proportion of patients.
Current or past combined treatment with IS and TNFα antagonists, considered as an adjustment variable, was identified as a risk factor for overall cancer in CD, although less significant than perforating CD. This observation, representing one of the main findings of the study, is in agreement with a recent study, 34 although conflicting data are reported. 1, 32, 33 As for IBD behaviour, differences in terms of study design and populations may account for the observed discrepancies. In the present study, treatment with anti-TNFα and/or IMM at any time during the study period was considered, and treatments reported at time of enrolment were updated during the 3 years' follow-up. These observations suggest the reliability of the reported findings. Combined IS and anti-TNFα treatment was also identified as a risk factor for overall cancer when data from CD and UC patients were grouped into one IBD group. Conversely, IS and/or anti-TNFα treatments did not appear to increase the cancer risk in UC, possibly due to the low proportion of treated patients. Whether IS monotherapy may increase the overall cancer risk is debated. 1, 32, 33, 35 Several studies report no excess risk using IS, 36 although the CESAME study, including NMSC, reported a higher risk. 11 On the other hand, anti-TNFα monotherapy currently appears not to increase the overall cancer risk. 1, 5, 6, 7, 8, 9, 10, 11, 12, 32, 33, 34 IMM are indicated in severe IBD, including perforating CD and extensive UC. 5, 6 As present findings identified these characteristics as risk factors for cancer, the possible relationship between IBD phenotypes and IMM in determining the cancer risk is being further defined in a longer follow-up.
In CD, perianal disease was identified as a risk factor for CRC, but not for overall cancer or for extracolonic cancers. Anal adenocarcinomas arising from perianal fistulas have been reported in CD, 1, 32 but data regarding perianal CD as a risk factor for CRC are lacking. IMM have been reported to reduce the risk of CRC in severe and extensive IBD colitis. 1, 29, 32 In CD and in the whole group of IBD patients, treatment with IS and anti-TNFα was identified as a risk factor for overall cancer and for extracolonic cancers, but not for CRC. This finding further supports that controlling inflammation by using IMM may reduce the risk of colitis-associated CRC in IBD. A high proportion of IBD patients [91.2%] was on maintenance treatment with 5-ASA, thus not allowing a proper assessment of the role of 5-ASA for preventing CRC and SBC. However, the observed incidence of these cancers was comparable to the general IBD population. 32 Further supporting that the severity of IBD may increase the cancer risk, in UC not only extensive colitis, but also disease-related surgery were identified as risk factors for overall cancer and for CRC. Accordingly, disease-related surgery was observed in a higher proportion of UC patients with cancer [p = 0.0007], whereas the same finding was not observed in CD, due to the high frequency of surgery in CD [> 50%]. In UC, disease-related surgery was associated with a 5-fold increased risk of overall cancer. This observation appeared mainly related to patients requiring colectomy for CRC, although disease-related surgery was at the limit of statistical significance as risk factor for extracolonic cancers. Disease-related surgery was indeed a risk factor for extracolonic cancers in the whole group Inflammatory Bowel Disease Phenotype and Cancerof IBD patients, but not in CD and in UC groups separately considered. An explanation for this apparent discrepancy is that in both CD and UC, disease-related surgery as risk factor for extracolonic cancers was at the limit of the statistical significance. When data from CD and UC patients were grouped into one IBD group, both disease-related surgery and combined IS and anti-TNFα treatment were therefore identified as risk factors for extracolonic cancers. These findings further support a role for severe IBD often requiring surgery and IMM, in determining the cancer risk.
Age at the latest visit was not a significant risk factor, as cases and controls were matched for this variable of adjustment. IBD duration increased the CRC risk, as expected. 1, 6, 29, 32 The same finding was not observed when UC and CD were separately considered, due to the relatively limited number of cases [n = 19; n = 24, respectively].
Clinical characteristics and the cumulative incidence of cancer in IBD were comparable to the general IBD population, 1, 18, 32, 33 thus supporting the reliability of our findings. This is further suggested by the observation that IBD duration [not matched variable] was comparable between cases and controls. Patients and controls were not matched for smoking nor for family history of cancer, although these may possibly be relevant for some types of malignancies. As data were prospectively recorded, these risk factors invariably changed several times during the 3 years' follow-up. Therefore, an accurate and updated match for smoking and for family history of cancer appeared not to be guaranteed for each patient and control recruited from the 16 centres. This is particularly true for incident cancers occurring in each family member of each patient and control during the 3 years' follow-up. Supporting these considerations, to the best of our knowledge, data from prospective multicentre studies assessing risk factors for incident cancer in IBD patients and controls matched for all these variables are lacking. 1, 2, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34 However, the observed percentage of smokers did not differ between CD and UC cases and controls, matched for gender and age. The expected higher frequency of smokers in CD vs UC 5, 6 was significant only for patients without cancer [CD-C vs UC-C; p < 0.0001]. This may suggest a role for smoking in determining the cancer risk in UC, although this risk factor was not statistically significant. The low proportion of both smokers and smoking-related cancers observed in our population may account for this finding. Although no scheduled surveillance protocols were planned at enrolment, routine clinical practice guidelines/consensus were followed by the referral IBD-dedicated, experienced gastroenterologist in each centre. However, as not scheduled at entry, a minority of patients may have not followed the surveillance programme [particularly for extra-colonic cancers]. Nevertheless, the observation that all patients concluded the followup at 3 years and that detailed information of characteristics of cancer were timely available for all patients, suggests good compliance of the study population and reliability of the reported findings. A high frequency of recurrent cancer was observed, in agreement with recent observations. 37, 38 thus representing one of the new messages of our study.
Although a large IBD population was considered, the number of incident cancers [n = 174] allowed only the assessment of risk factors for cancer overall, for CRC, and for extracolonic cancers. Some of the observed associations for the overall population in contrast to the individual subtypes of IBD [CD or UC] may indeed be related to the small number of incident cases of cancer in the subtypes and to the relatively short period of both observation and IBD duration. However, in both CD and UC groups, the median IBD duration appeared not short [from 12 to 13.5 years], although showing wide inter-individual variations [from 1 to 54 years]. Risk factors for specific cancer subtypes, excluded from the aims of the study, are being assessed in a longer follow-up. Nevertheless, the more frequent cancers involved the digestive system, the skin, and the urinary tract, supporting recent studies. 35 IS were used by almost half [11 out of 21] of IBD patients with urinary tract cancer, recently associated with IS use. 35 SBC and lymphoma were observed only in CD, and CRC was the most frequent cancer of the digestive system, as expected. 1, 6, 29, 30, 31, 32, 33 CRC and SBC represented more than two-thirds of cancers, supporting the role of chronic inflammation in these cancers. SBC developed only in small-bowel CD, showing a high frequency [7. 07%], thus supporting a role for the sequence 'uncontrolled inflammation-dysplasia-cancer' not only in CRC, but also in SBC. 28, 39 This is also suggested by the finding that, despite the small sample, seven out of eight CD patients with SBC never received IS or TNFα antagonists. Conversely, although the incidence of SBC was at least equivalent to that of lymphoma, half of lymphomas were treated with IS or anti-TNFα [and still more in some extracolonic cancers, principally NMSC]. SBC was diagnosed either at CD onset or after a long history of stricturing CD. Despite the small sample, these preliminary findings suggest that both refractory/ recurrent obstructions at CD onset and a long history of stricturing small-bowel CD may represent risk factors for SBC even in patients never treated with IMM.
The present prospective, multicentre, nested case-control study supports that penetrating CD and extensive UC represent significant risk factors for cancer in general. In the tested IBD population, the cumulative incidence of cancer was higher in CD than in UC, whereas present or past treatments with IS and anti-TNFα, considered as an adjustment factor, slightly increased the risk of overall cancer and of extracolonic cancers in CD. On the other hand, the risk of CRC in CD was not increased by IS and TNFα antagonists, thus supporting that controlling severe inflammation by using IMM may reduce the risk of CRC in IBD. 1, 29, 30, 31, 32, 33 These findings suggest that IBD patients showing an aggressive course associated with severe and diffuse lesions, as observed in perforating CD and in extensive UC, may bear an increased overall cancer risk. Clinical characteristics of IBD should be considered among risk factors for cancer in general, particularly in young patients with perforating CD or extensive UC, most often requiring immunomodulators.
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